Long non-coding RNAs and circular RNAs in tumor angiogenesis: From mechanisms to clinical significance

Chen-Guang Liu,1,2,9 Juan Li,3,9 Yanhua Xu,1,9 Wan Li,4 Shu-Xian Fang,5 Qing Zhang,6,7 Hong-Wu Xin,1,2,8 and Zhaowu Ma1,2

Long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) execute a wide array of functions in physiological and pathological processes, including tumor progression. Angiogenesis, an elaborate multistep process driving new blood vessel formation, accelerates cancer progression by supplying nutrients and energy. Dysregulated lncRNAs and circRNAs can reportedly impact cancer progression by influencing angiogenesis. However, the expanding landscape of lncRNAs and circRNAs in tumor progression-dependent angiogenesis remains largely unknown. This review summarizes the major functions of angiogenic lncRNAs (Angio-LncRs) and angiogenic circRNAs (termed Angio-CircRs) and their cancer mechanisms. Moreover, we highlight the commonalities of lncRNAs and circRNAs in epigenetic, transcriptional, and post-transcriptional regulation as well as illustrate how Angio-LncRs and Angio-CircRs induce cancer onset and progression. We also discuss their potential clinical applications in diagnosis, prognosis, and anti-angiogenic therapies.

INTRODUCTION

Non-coding RNAs (ncRNAs) are transcribed from the genome but generally lack protein-coding potential. Long ncRNAs (lncRNAs) and circular RNAs (circRNAs) are two major groups of large ncRNAs that play key roles in various pathophysiological processes, especially cancers.1–3 lncRNAs are widely defined as a large and heterogeneous class of regulatory transcripts that are at least 200 nt long.4,5 circRNAs are also a subtype of endogenous ncRNAs with tissue- and cell-specific expression patterns, whose biogenesis is regulated by a particular form of alternative splicing, termed backsplicing.6 With the development of high-throughput technologies and extensive research reports, lncRNAs and circRNAs have gained wide attention for their roles in the development of many human diseases.5,7 lncRNAs and circRNAs are generally low in abundance; however, they are significantly differentially expressed in specific cell types, tissues, developmental stages, and disease states.8–10 Recently, accumulating independent studies have shown that the dysregulation of lncRNAs and circRNAs plays multifunctional roles in cancer progression, including tumor angiogenesis.11,12 However, the commonalities of their functions and mechanisms in tumor progression-dependent angiogenesis remain largely obscure.

Angiogenesis is a multistep process that involves the formation of new blood vessels from pre-existing vessels, contributing to cancer onset and progression.13 Within tumors, the angiogenic switch is activated, thereby inducing the continuous formation of new blood vessels.14 Targeting angiogenesis is an effective therapeutic strategy against cancer that has been applied in a plethora of cancers.15 Of note, diverse arrays of molecules play multifaceted roles in the mechanisms underlying tumor angiogenesis.16–17 To date, the role of ncRNAs in manipulating cancer phenotypes across various tumor types has been studied, and lncRNAs and circRNAs are emerging as part of a widespread regulatory mechanism that orchestrates gene expression in tumor angiogenesis.

Recent reviews have mainly focused on the respective roles of lncRNAs and circRNAs in angiogenesis;18–22 however, their molecular mechanisms and commonalities have not been deeply explored, especially in tumor angiogenesis. This review summarizes the
expanding landscape of lncRNAs and circRNAs ranging from epigenetic to transcriptional and post-transcriptional regulation in tumor angiogenesis. This work is the first review on the advance of circRNAs in tumor angiogenesis and the functional commonalities of lncRNAs and circRNAs. Furthermore, we illustrate the roles of angiogenesis-related lncRNAs and circRNAs in multitumor development and explore their great potential in tumor angiogenesis as new biomarkers and tumor therapeutic targets.

**lncRNAs AND circRNAs: FUNCTIONAL COMMONALITIES IN TUMOR ANGIOGENESIS**

**Functional commonalities between lncRNAs and circRNAs**

Increasing independent research has indicated that lncRNAs and circRNAs can play a broad and diverse spectrum of pathophysiological roles, including tumor angiogenesis. Mechanistically, lncRNAs and circRNAs can directly interact with diverse partners in the form of cis or trans interactions to regulate gene expression and signal transduction. Based on their action mechanism, lncRNAs are generally divided into four functional archetypes: signal, decoy, guide, and scaffold. Interestingly, similar complex mechanisms of circRNAs have emerged in a wide variety of cell types and diseases. Moreover, both lncRNAs and circRNAs exhibit common functional features that have not been previously appreciated.

The expanding mechanisms of lncRNAs and circRNAs orchestrating gene expression can be summarized into the following aspects (Figure 1): (1) at the epigenetic layer, lncRNAs and circRNAs recruit diverse epigenetic factors to orchestrate gene transcription and signal transduction; (2) at the transcriptional level, gene transcription is regulated by lncRNAs and circRNAs via interaction with transcriptional factors and co-factors or target gene promoters; (3) at the post-transcriptional level, lncRNAs and circRNAs modulate precursor (pre-)mRNAs and mRNAs of many genes by interacting with microRNAs (miRNAs), splicing factors, and diverse RNA-binding proteins (RBPs); (4) lncRNAs and circRNAs orchestrate a broad repertoire of RNA or protein modifications to affect their activation and stability; and (5) notably, lncRNAs and circRNAs can encode functional peptides that exert crucial roles in distinct biological processes.

Taken together, gene regulation by lncRNAs and circRNAs is an extensive and complex process that exists in a plethora of human diseases. The emerging commonalities of lncRNAs and circRNAs show expanding mechanisms that provide hope for new therapeutic interventions in diverse diseases. However, the detailed functions of most lncRNAs and circRNAs are still unclear and require detailed, comprehensive research in preclinical models.

**lncRNAs and circRNAs: Novel players in tumor angiogenesis**

Angiogenesis is a complicated multistep process stimulated by various pro-angiogenic factors (such as vascular endothelial growth factor [VEGF]). The vascular network’s original dynamic balance is compromised, the capillary basement membrane degrades, and endothelial cells begin to migrate and proliferate, forming new primary capillary networks. Capillaries undergo arteriovenous differentiation and remodeling in the form of sprouting and intussusception, and this primitive network expands widely to form a network of vascular systems with complex functions. Generally speaking, angiogenesis occurs in response to physiological and pathological processes, including tumor growth, inflammation, tissue regeneration, and reproduction. During tumor growth, a large number of new vascular systems are needed to provide adequate nutrients and
remove metabolic waste. Therefore, blocking tumor blood vessel formation is equivalent to inhibiting tumor growth and progression; however, tumor-induced blood vessels often present morphological disorders characterized by precocious vascular structure, tortuosity, poor permeability, and dysfunction. These abnormal vascular networks create a hypoxic microenvironment within the tumor, triggering the expression of multitudinous oncogenes and inducing immunosuppression and metastasis. Therefore, some scholars think that anti-angiogenic therapy may facilitate the metastasis and invasion of cancer cells by activating a cancer cell hypoxic response. However, this is a controversial view and may not occur during clinical therapy. In essence, anti-angiogenesis has always been the focus of anticancer drug development due to the critical role of angiogenesis in tumor growth and progression.

VEGF and its receptors are one of the well-documented signaling pathways in tumor angiogenesis. In most solid tumors, hypoxia is one of the key drivers of angiogenesis and induces the expression of angiogenic factors via hypoxia-inducible factors (HIFs). In tumor hypoxia, HIF-1α induces the expression of VEGF, which activates VEGF receptor 2 (VEGFR2), thereby stimulating tip cell migration from the arteries to initiate angiogenesis. Notch regulates the proliferation and migration of the tip cells and stalk cells, and Neuropilin-1 accelerates the separation of arteries and veins, thus continuously promoting the establishment of the vascular system network. Currently, IncRNAs and circRNAs have been identified as novel and versatile players involved in tumor angiogenesis via manipulating angiogenic factors. Specific well-known IncRNAs (such as H19 and MALAT1) have been identified as vital modulators of angiogenic factors. Similarly, circRNA circRhoC enhances ovarian cancer (OC) angiogenesis by regulating the expression of VEGFA. Increasing evidence indicates that IncRNAs and circRNAs are intricately involved in tumor angiogenesis via diverse mechanisms.

Recently, Yu and Wang named IncRNAs regulating angiogenesis and vascular diseases as Angio-LncRs. Herein, we have termed the circRNAs that modulate angiogenesis and vascular disease as Angio-CircRs. In reality, Angio-LncRs and Angio-CircRs play extensive regulatory roles in distinct vascular diseases, such as cancer, atherosclerosis, aneurysm, and diabetic retinopathy, among others. In the field of oncology, the study of ncRNAs has attracted great attention and made rapid progress. Reviewing the current reports of Angio-LncRs and Angio-CircRs in tumor angiogenesis could help further explore the novel potential targets of ncRNA-related anti-tumor strategies and provide clinical enlightenment for cancer diagnosis and treatment.

**ANGIO-LncRs: MECHANISMS OF ACTION IN CANCERS**

Current studies have identified that the dysregulation of IncRNAs contributes to tumorigenesis and tumor progression. Generally, IncRNAs exert tumor-promotive and -suppressive roles to regulate gene expression via diverse mechanisms of action. Accumulating evidence shows that IncRNA-modulated cancer progression, especially tumor angiogenesis, remains to be further explored. In the subsequent sections, we comprehensively summarize the expanding functions and mechanisms of IncRNAs in tumor angiogenesis (Table 1; Figure 2), especially inducing the expression of several key angiogenic mediators, including VEGF and VEGFR.

**Angio-LncRs influence chromatin modification**

Multiple lines of studies have revealed that many IncRNAs influence epigenetic changes by recruiting or interacting with chromatin remodeling complexes to specific genomic loci, thus leading to epigenetic activation or silencing of gene expression. Enhancer of zeste homolog 2 (EZH2), a catalytic subunit of the polycomb repressive complex 2 (PRC2), can catalyze the methylation of histone H3 lysine-27 for epigenetic regulation. Emerging studies have shown that numerous IncRNAs interact with PRC2 for the epigenetic regulation of tumor angiogenesis. For instance, IncRNA PVT1 is significantly elevated in cholangiocarcinoma (CCA). Mechanistically, by binding to PRC2, PVT1 could mediate the histone methylation of the promoter of angiopoietin-like 4 (ANGPTL4) via reducing the interaction between EZH2 and H3K27 trimethylation sites throughout the promoters of ANGPTL4, resulting in the promotion of cell angiogenesis, cell proliferation, migration, and apoptosis (Figure 2A). Similarly, H19 is closely related to a plethora of tumor types via manipulating cell proliferation, invasion, and angiogenesis. Silencing of H19 inhibited the capability of EZH2 to recruit methyl groups to the promoter region of the angiogenesis inhibitor vasohibin-1 (VASH1), thereby elevating VASH1 expression and secretion of human angiopoietic mesenchymal stem cells (HAMSCs) and restraining angiogenesis by interacting with EZH2. A novel Kaposi’s sarcoma-associated herpesvirus (KSHV) reactivation-activated IncRNA, LINC00313, suppresses endothelial cell migration and tube formation via interaction with HIV Tat. Mechanistically, LINC00313 blocks endothelial cell angiogenesis-related properties by binding to PRC2 and decreasing migration-regulating gene expression. In addition to the interaction with PRC2, certain IncRNAs also bind to other epigenetic factors. Another hypoxia-mediated IncRNA, GATA6-AS, is up-regulated in endothelial cells under hypoxic conditions. Silencing of GATA6-AS inhibits transforming growth factor (TGF)-β-induced epithelial-to-mesenchymal transition (EMT) and tumor angiogenesis. Mechanistically, GATA6-AS interacts with the epigenetic mediator LOXL2 to regulate endothelial gene transcription by inducing histone methylation. Taken together, increasing evidence shows that dysregulation of IncRNAs contributes to tumor angiogenesis and tumor progression via the recruitment of chromatin-modifying enzymes and their subunits.

In addition to histone methylation, DNA methylation is an important epigenetic modification involved in the expression of many cancer-related genes. For example, BZRAP1-AS1 suppresses the transcription of thrombospondin-1 (THBS1) via interaction with the DNA methyltransferase 3B and induction of methylation of the THBS1 promoter; this promotes the proliferation, migration, angiogenesis, and tumor growth of hepatocellular carcinoma (HCC) (Figure 2A). On the contrary, IncRNA AK001058 promotes tumor growth,
| Mechanism/level | IncRNA | Expression | Function | Molecular mechanism | Cancer type         | Refs. |
|----------------|--------|------------|----------|---------------------|---------------------|------|
| **Epigenetic regulation** |        |            |          |                     |                     |      |
|               | PVT1   | up         | pro-angiogenesis | interacts with PRC2 and inhibits transcription of ANGPTL4 | CCA                  | 58   |
|               | H19    | up         | pro-angiogenesis | increases VASH1 expression in HAMSCs via binding to EZH2 | multiple tumors      | 56   |
|               | LINC00313 | down      | anti-angiogenesis | binds PRC2 and decreases transcription of cell migration-regulating genes | Kaposi sarcoma       | 59   |
|               | BZRAP1-AS1 | up        | pro-angiogenesis | inhibits THBS1 transcription by interacting with DNMT3b to induce THBS1 promoter methylation | HCC                 | 60   |
|               | AK001058 | up         | pro-angiogenesis | promotes the methylation level of ADAMTS12 to decrease the expression of ADAMTS12 | CRC cell lines       | 61   |
|               | CRNDE   | up         | pro-angiogenesis | regulates the mTOR signaling pathway through epigenetic mechanisms | hepatoblastoma       | 62   |
| **Transcriptional regulation** |        |            |          |                     |                     |      |
|               | RAB11B-AS1 | up         | pro-angiogenesis | enhances the expression of VEGFA and ANGPTL4 by increasing the recruitment of RNA Pol II | breast cancer cell lines | 61   |
|               | LINC00312 | up         | pro-angiogenesis | promotes the expression of VEGFA by binding to YBX1 | lung adenocarcinoma | 63   |
|               | Linc00665 | up         | pro-angiogenesis | interacts with YB-1 to promote transcription of ANGPT4, ANGPTL3, and VEGFA | lung adenocarcinoma | 64   |
|               | PVT1    | up         | pro-angiogenesis | activates transcription of VEGFA and PVT1 by interacting with STAT3 | gastric cancer       | 65   |
|               | CPS1-IT1 | down      | anti-angiogenesis | competitively combines with BRG1 to inhibit the expression of Cyr61 and its downstream targets VEGF and MMP9 | melanoma             | 66   |
|               | HOTAIR  | up         | pro-angiogenesis | activates VEGFA transcription by directly targeting the VEGFA promoter, or upregulates GRP78 expression to mediate VEGFA and Ang2 expression | nasopharyngeal carcinoma | 67   |
|               | LINC00284 | up         | pro-angiogenesis | recruits NF-κB1 and downregulates MEST expression | ovarian cancer       | 68   |
|               | LINC00858 | up         | pro-angiogenesis | upregulates HNF4α and downregulates WNK2 expression | colon cancer         | 69   |
|               | HNF1A-AS1 | up         | pro-angiogenesis | increases the OTX1 expression via interacting with transcription factor PBX3 to activate the ERK/MAPK pathway | colon cancer         | 70   |
|               | MALAT1  | up         | pro-angiogenesis | sponges miR-126-5p to increase expression of VEGFA, SLUG, and TWIST | CRC                  | 71   |
|               | MALAT1  | up         | pro-angiogenesis | increases VEGFA expression by sponging miR-140, re-directing the M2 polarization of macrophages | HCC                  | 72   |
|               | MALAT1  | up         | pro-angiogenesis | promotes VEGF expression via sponging miR-145 | breast cancer       | 73   |
|               | MALAT1  | up         | pro-angiogenesis | competitively binds miR145-5p and elevates the NEDD9 protein expression | NSCLC                | 74   |
| **Sequestering miRNAs** |        |            |          |                     |                     |      |
|               | TUG1    | up         | pro-angiogenesis | sponges miR-143-5p to mediate HIF-1α expression | osteosarcoma         | 75   |
|               | TUG1    | up         | pro-angiogenesis | sequesters miR-299 to induce VEGF expression | glioblastoma         | 76   |
|               | TUG1    | up         | pro-angiogenesis | sponges miR-34a-5p and increases VEGFA expression | hepatoblastoma       | 77   |
|               | ZFAS1   | up         | pro-angiogenesis | SP1-induced ZFAS1 upregulates VEGFA via competitively binding miR-150-5p, thereby activating the Akt/mTOR signaling pathway | CRC                  | 78   |
|               | HULC    | up         | pro-angiogenesis | upregulates the TF E2F1 by sponge miR-107 to increase SPHK1 expression | HCC                  | 79   |

(Continued on next page)
accounting for increased cell apoptosis and tumor angiogenesis in colorectal cancer (CRC), which partly depends on the methylation of ADAMTS12, a potential anti-oncogene located on chromosome 5, and resulting in increased expression of VEGFA and angiopoietin II.61 Additionally, various lncRNAs are also associated with chromatin-modifying complexes to manipulate tumor growth and angiogenesis in distinct signaling pathways, such as the mammalian target of rapamycin (mTOR) signaling pathway.62 Collectively, a growing number of studies have shown that lncRNAs epigenetically regulate transcription of tumor angiogenesis-related genes by either directly or indirectly affecting chromatin-modifying factors. This broadens our understanding of angiogenesis and provides a positive direction for the potential application of therapeutic intervention in regulating tumor progression at the epigenetic level.

**Angio-LncRs in transcriptional regulation**

Studies have shown that lncRNAs can manipulate gene transcription by binding specific transcription factors (TFs) to promoters of adjacent or distant genes, thus modulating tumor angiogenesis. For instance, in hypoxic breast cancer cells, RAB11B-AS1 is induced by HIF-2, promoting tumor angiogenesis and distant metastasis in response to hypoxia. Mechanistically, RAB11B-AS1 facilitates the transcription of VEGFA and ANGPTL4 by promoting RNA polymerase II recruitment (Figure 2B).11 The levels of LINC00312 were high in lung adenocarcinoma (LUAD) patients, which positively correlated with tumor node metastasis. LINC00312 promotes the transcription of VEGFA by directly binding to the TF Y-box binding protein 1 (YB-1, YBX1) and inducing migration and vasculogenic mimicry (VM) (Figure 2B).63 Similarly, in LUAD cells, linc00665 suppresses ubiquitination-dependent proteolysis and induces YB-1 nuclear translocation by directly binding to YB-1. The accumulated nuclear YB-1 promoted transcription of VEGFA, ANGPTL4, and ANGPTL3 by binding to their promoters, thus facilitating tumor angiogenesis.64 The lncRNA PVT1 level was elevated and markedly correlated with poor prognosis in gastric cancer (GC). Mechanistically, PVT1 directly interacted with phospho-STAT3 in the nucleus, thereby promoting VEGFA expression by activating the VEGFA promoter to stimulate tumor angiogenesis. Moreover, STAT3 could bind to the PVT1 promoter and facilitate its transcription, which established a positive feedback loop of PVT1 and STAT3 to strengthen...
their oncogenic effects. A well-known lncRNA, HOTAIR, was extremely abundant in nasopharyngeal carcinoma (NPC); it promoted tumor cell growth and angiogenesis by directly activating VEGFA transcription via targeting VEGFA promoter and upregulating the GRP78/VEGFA/Ang2 axis. lncRNA CPS1-IT1 acts as a tumor suppressor and suppresses EMT, cell migration, and angiogenesis in melanoma. Mechanistic studies uncovered that CPS1-IT1 impedes the transcription of the angiogenic factor cysteine-rich 61 (Cyr61) by blocking the binding of BRG1 to the Cyr61 promoter.

In addition to VEGF/VEGFA, other angiogenic factors are mediated by different lncRNAs to induce cancer angiogenesis and development. For example, Ruan and Zhao identified that LINC00284 is associated with angiogenesis during OC development. Silencing LINC00284 inhibits tumor angiogenesis via recruitment of nuclear factor kB1 (NF-kB1), thereby upregulating mesoderm-specific transcript (MEST) in OC. Another example, LINC00858, is mainly located in the nucleus and exerts a promotive role in colon cancer growth. Functional assays uncovered that LINC00858 elevates the transcription of HNF4α, thereby promoting angiogenesis by the HNF4α/WNK2 axis. Additionally, lncRNA HNF1A-AS1 is highly expressed in colon cancer. HNF1A-AS1 promotes OTX1 transcription via interacting with the TF PBX3, thereby activating the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway in colon cancer. Taken together, lncRNAs may act as transcriptional activators or inhibitors, which can directly or
indirectly regulate the transcription of angiogenesis-related genes, thereby affecting the progression of various malignant tumors.

**Sequestering miRNAs**

LncRNAs can also function as competing endogenous RNAs (ceRNAs) to compete together with miRNAs and dampen the gene expression of miRNA targets, thus participating in post-transcriptional regulation. This section provides an overview of the direct and indirect mechanisms of LncRNAs by sponging diverse miRNAs to affect tumor angiogenesis. For instance, MALAT1, a widely reported LncRNA, is highly expressed in a variety of tumors. Functional assays indicated that YAP1-mediated MALAT1 could sponge miR-126-5p to facilitate the expression of VEGFA, SLUG, and TWIST, which could promote CRC angiogenesis and EMT (Figure 2C). Similarly, MALAT1 exerts a promotive role in regulating tumorigenesis by sponging miR-140 or miR-145, thereby increasing VEGF and VEGF expression in HCC and breast cancer. Additionally, estrogen receptor β promotes the progression of lung cancer by upregulating MALAT1 to alter miR-145-5p/NEDD9 signaling, resulting in the facilitation of VM formation and cell invasion. Similar to MALAT1, the LncRNA TUG1 is also significantly highly expressed in various tumors. Cancer-associated fibroblast (CAF)-derived TGF-β promotes TUG1 expression, and the interplay between CAFs and osteosarcoma (OS) cells induces TUG1 to facilitate OS angiogenesis, proliferation, and metastasis. TUG1 acts as a sponge for miR-143-5p, thereby elevating HIF-1α levels to promote VEGF expression (Figure 2C). Similarly, TUG1 knockdown suppresses angiogenesis and tumor growth by decreasing VEGFA expression via upregulation of miR-299 and miR-34a-5p in glioblastoma and hepatoblastoma, respectively. Several groups have shown that many LncRNAs (PVT1, DANC, LINC0116, linc01105, and SNHG15) contribute to tumor angiogenesis and progression, upregulating VEGF/VEGFA expression by competitively binding to distinct miRNAs in a wide variety of cancers types. Recently, LncRNAs were reported to be involved in cellular signaling pathways such as the NF-kB, phosphatidylinositol 3-kinase (PI3K)/AKT, mTOR, and Wnt/β-catenin pathways. As relatively upstream regulatory molecules, LncRNAs act by impacting downstream molecules via competitively sponging miRNAs. For example, LINC01410 facilitates GC angiogenesis and metastasis via interaction with miR-532-5p, increasing NC2 expression and activating the NF-kB pathway. Similarly, PTENP1, a pseudogene of PTEN, inhibits the oncogenic PI3K/AKT pathway by sponging miR-17, miR-19b, and miR-20a, which results in eliciting pro-death autophagy and dampering angiogenesis. Additionally, MCM3AP-AS1 and HOXA-AS2 regulate the PI3K/ AKT pathway and contribute to glioblastoma multiforme (GBM) angiogenesis by influencing miRNA targets. The SP1-induced LncRNA ZFAS1 contributes to CRC progression by elevating VEGFA levels via sequestering miR-150-5p, thereby activating the Akt/mTOR signaling pathway.

Furthermore, LncRNAs indirectly regulate the expression of angiogenesis-related genes through miRNA-mediated TFs. For example, XIST and LINC00339 can act as ceRNAs to sponge miR-137 and miR-539-5p, elevating the expression of the miRNA targets (FOXC1, ZO-2, TWIST1) by increasing promoter activity and downstream gene expression, thereby promoting glioma angiogenesis. IncRNA HULC sequesters miR-107 via a ceRNA model, which increases the transcription of miR-107 target E2F1. As a result, the TF E2F1 binds to the SPHK1 promoter and enhances SPHK1 transcription to induce HCC angiogenesis. In addition, LncRNAs modulate the expression of other angiogenic factors via sequestering different miRNAs to mediate tumor angiogenesis. For example, H19, SNHG16, and MCM3AP-AS were significantly upregulated in diverse cancer types; they regulated the expression of vascular endothelial growth factor (VEGF) and other angiogenic factors. Taken together, current progress indicates that LncRNAs often act as ceRNAs in tumor angiogenesis and may serve as promising targets for cancer therapy.

**Angio-LncRs interact with mRNAs**

Many studies report that LncRNAs can bind mRNAs to affect their stability and the translation process, thus regulating the expression and secretion of related molecules for tumor progression and tumor angiogenesis. For instance, LncRNA-APC1, as a downstream factor of adenomatous polyposis coli (APC) in CRC, suppresses CRC angiogenesis and metastasis by inhibiting exosome production via directly interacting with the Rab5b mRNA, which results in decreased Rab5b mRNA stability. This study revealed that CRC-derived exosomes regulated the LncRNA-APC1/Rab5b axis to inhibit the angiogenesis of CRC, linking APC signaling to the canonical Wnt pathway (Figure 2D). Another LncRNA, MV1H, activates CRC angiogenesis via interacting with the RPS24c isoform and enhances each other’s stability, thereby inhibiting the secretion of PGK1 (Figure 2D). LncRNA TPT1-AS1 directly binds nuclear factor 90 (NF90) and induces the interplay between NF90 and the VEGFA mRNA, thus enhancing VEGFA mRNA stability and facilitating CRC angiogenesis and metastasis. Moreover, LINC00346 can bind to the ZNF655 mRNA by its Alu elements, thereby promoting the degradation of the ZNF655 mRNA in a Staufen1-mediated mRNA decay manner. Furthermore, ANKHDI1 targets LINC00346 and elevates its stability. ZNF655 targets the promoter region of ANKHDI and forms a positive feedback loop that contributes to glioma angiogenesis. Hypoxia plays an oncogenic role in angiogenesis, metabolism, tumor invasion, and metastasis. A novel LncRNA termed HITT at translation level (HITT) is downregulated in colon cancer. Mechanistically, HITT inhibits HIF-1α translation by directly interacting with YB-1 and blocking the interplay between YB-1 and the 5’ UTR of HIF-1α. Furthermore, HITT and HIF-1α form an autoregulatory feedback loop, where HIF-1α destabilizes HITT by inducing miR-205, which directly targets HITT for degradation. In summary, LncRNAs play a diverse spectrum of roles by regulating mRNA...
Angio-LncRs induce protein modifications

Accumulating studies have revealed that multifaceted functions of lncRNAs are achieved by protein modification to manipulate the activation of proteins. The post-translational protein modifications, such as phosphorylation and ubiquitination, have been modulated by distinct ncRNAs. lncRNAs also manipulate oncogenic and tumor-suppressive protein activation and stability, thereby manipulating tumor phenotypes involved in angiogenesis. For example, the IncRNA CamK-A is highly expressed in many human cancer types and activates the Ca^{2+}/calmodulin-dependent kinase PNCK, which phosphorylates IκBα and triggers calcium-dependent NF-κb activation. This results in the active expression of the NF-κb target genes, such as VEGF, GLUT3, IL-6, and IL-8, promoting cancer microenvironment remodeling, including macrophage recruitment, angiogenesis, and tumor progression (Figure 2E).85 Furthermore, the expression of FLANC was increased and associated with poor survival. Mechanistically, elevated FLANC prolonged the half-life of phosphorylated STAT3, promoting VEGFA transcription and inducing CRC angiogenesis. Moreover, pharmacological targeting of FLANC significantly suppressed the metastases of CRC.86 lncRNA-MM2P levels are elevated during M2 polarization but decreased in M1 macrophages. Silencing of lncRNA-MM2P significantly inhibited M2 polarization and macrophage-induced tumorigenesis and tumor angiogenesis by regulating STAT6 phosphorylation.87

In addition to modulating protein phosphorylation, lncRNAs mediate ubiquitination to regulate the activation and ubiquitination-dependent degradation of distinct proteins. As an example, lnc-CCDST is significantly downregulated in cervical cancer (CC) tissues. Mechanistically, lnc-CCDST interacts with DHX9 and enhances its degradation via the ubiquitin-proteasome pathway by recruiting the E3 ubiquitin ligase MDM2. In HPV-positive cell lines, HPV oncogenes E6 and E7 can abolish the negative effects of lnc-CCDST by increasing DHX9 expression, which facilitates CC cell motility and angiogenesis (Figure 2E).88 Another lncRNA, NBAT1, inhibits GC progression and capillary tube formation. Further analysis uncovered that NBAT1 interacted with SRY-related high-mobility-group box 9 (Sox9) and reduced its protein stability by promoting polyubiquitination and proteasome-dependent degradation. Furthermore, Sox9 acts as a TF and interacts with the NBAT1 promoter to diminish its transcription, forming a negative feedback loop of NBAT1 and Sox9.89 Similarly, TNK2-AS1 levels were markedly increased in non-small cell lung cancer (NSCLC) and promoted oncogenesis, angiogenesis, and metastasis. Mechanistically, TNK2-AS1 directly binds STAT3 and enhances its protein stability by weakening its proteasome-mediated degradation. In return, STAT3 occupies the TNK2-AS1 promoter to promote its transcription. The positive feedback loop between TNK2-AS1 and STAT3 enhances STAT3 signaling by elevating VEGFA expression.90 Taken together, lncRNAs directly or indirectly interact with key proteins through different mechanisms of action and orchestrate tumor angiogenesis by impacting protein modifications such as phosphorylation and ubiquitination.

Angio-LncRs encode functional peptides

Although lncRNAs are not widely translated by definition, emerging studies have shown that lncRNAs can encode functional peptides to regulate various biological processes, including tumor progression.6 As an example, Huang et al.112 identified that the lncRNA HOXB-AS3 encodes a conserved 53-aa peptide that suppresses aerobic glycolysis and inhibits colon cancer growth. The biological effect of lncRNA-encoded peptides has attracted considerable attention. Moreover, this novel mode of action has been found to regulate tumor angiogenesis and progression. LINC00908, which encodes a 60-aa functional polypeptide termed automatic speech recognition and proteasome-dependent angiogenesis by disrupting endothelial barrier integrity. Functional
assays uncovered that circ-CCAC1 strengthens cell leakiness by sequestering EZH2 in the cytoplasm, thus promoting SH3GL2 transcription to decrease intercellular junction protein levels. Additionally, circ-CCAC1 facilitates CCA progression via sponging miR-514a-5p to enhance YY1 translation. YY1 acts as a TF to activate CAMLG transcription by directly binding to its promoter (Figure 3A). Overall, current studies have shown that circRNAs in influence angiogenesis by epigenetically inducing gene transcription, establishing a favorable microenvironment for tumor progression.

**Angio-CircRs mediate splicing and mRNA stability**

In addition to regulating gene transcription, circRNAs appear to orchestrate tumor angiogenesis by impacting post-transcriptional processes such as alternative splicing and mRNA stability. For example, circSMARCA5 regulates the VEGFA mRNA splicing by interacting with the splicing factor serine and arginine-rich splicing factor 1 (SRSF1), resulting in the production of pro-angiogenic (Iso8a) and anti-angiogenic (Iso8b) mRNA isoforms of VEGFA in GBM. SRSF1, a proximal splice site of VEGF, promotes the expression of pro-angiogenic isoforms (VEGF-Axxx), contributing to tumor angiogenesis. This study shows that circSMARCA5 is an upstream regulator of the ratio of pro-angiogenic to anti-angiogenic VEGFA isoforms within GBM cells, which suggests that circSMARCA5 acts as a promising prognostic anti-angiogenic biomarker (Figure 3B). Another novel circRNA, circPOK, is encoded by the Zbtb7a gene in mesenchymal tumor progression. circPOK interacts with the ILF2/3 complex to bind and stabilize interleukin (IL)-6 and VEGF mRNA, thereby inducing activation of Hedgehog/GLI1 and Wnt/β-catenin pathways. These findings indicate that circPOK exerts diverse functions in regulating mRNA transcription and stability (Figure 3B). Therefore, targeting angiogenesis-related circRNAs during cancer development and metastasis may be a promising RNA-based therapeutic approach.

**Angio-CircRs interacting with RBPs**

RBPs exert fundamental roles in orchestrating protein expression, RNA metabolism, and transport and localization of distinct transcripts. The binding of circRNAs to RBPs has a wide range of functions, such as affecting epigenetic regulation, transcriptional regulation, splicing regulation, and the formation of circRNAs themselves. Recent studies have shown that circRNAs directly bind to VEGFs and thus regulate tumor angiogenesis. For example, circRhoC, derived from the RhoC mRNA, was significantly highly expressed in advanced-stage OC and contributed to OC angiogenesis and metastasis. Mechanistic analysis indicated that circRhoC

| Table 2. The emerging roles of Angio-CircRs in various cancers |
|---------------------------------------------------------------|
| **Mechanism/level** | **circRNA** | **Expression** | **Function** | **Molecular mechanism** | **Cancer type** | **Ref.** |
| Epigenetic and transcriptional regulation | circ-CCAC1 | up | pro-angiogenesis | Increases SH3GL2 expression by sequestering EZH2 in the cytoplasm | CCA | 12 |
| Splicing and mRNA stability | circSMARCA5 | down | anti-angiogenesis | interacts with SRSF1 to regulate VEGFA mRNA Splicing | GBM | 114 |
| | circPOK | up | pro-angiogenesis | promotes the ILF2/3 complex to bind and stabilize interleukin (IL)-6 and VEGF mRNA | mesenchymal tumor | 115 |
| | circRhoc | up | pro-angiogenesis | directly binds and modulates VEGFA expression, sponges miR-302c to regulate VEGFA expression | ovarian cancer | 57 |
| | circ-GLI1 | up | pro-angiogenesis | interacts with p300 to upregulate Cyr61 via inducing activation of Hedgehog/GLI1 and Wnt/β-catenin pathways | melanoma | 116 |
| Interacting with RBPs | circ-ATXN1 | up | pro-angiogenesis | sponges miR-526b-5p to upregulate the expression of MMP2/VEGFA | glioma | 117 |
| | circSCAF1 | up | pro-angiogenesis | sponges miR-421 to promote SP1 expression, which activates the transcription of VEGFA | glioma | 118 |
| | circRNA-MYLK | up | pro-angiogenesis | sponges miR-29a to trigger VEGFA/VEGFR2 and the downstream Ras/ERK signaling pathway | bladder carcinoma | 119 |
| | circ0001429 | up | pro-angiogenesis | sponges miR-205-5p to increase VEGFA expression | bladder cancer | 120 |
| | circCCT3 | up | pro-angiogenesis | sponges miR-613 to upregulate VEGFA and WNT3 expression | CRC | 121 |
| | circ_0056618 | up | pro-angiogenesis | sponges miR-206 to upregulate CXCR4 and VEGFA | CRC | 122 |
| | circHIPK3 | down | anti-angiogenesis | sponges miR-558 to inhibit the expression of HPSE | bladder cancer | 123 |

Expression is in relation to normal tissue. These studies used human tissue samples. All circRNAs were measured with qRT-PCR in these studies. GBM, glioblastoma multiforme; PDAC, pancreatic ductal adenocarcinoma.
functioned not only as a miR-302e sponge to promote VEGFA translation but also directly bound and regulated VEGFA expression (Figure 3C). Additionally, circ-GLI1 interacted with p70S6K2 to induce GSK3β phosphorylation at Ser9, thereby blocking the binding of GSK3β with GLI1 and β-catenin, elevating their protein expression. This study uncovered that circ-GLI1 facilitates melanoma angiogenesis and metastasis by elevating Cyr61 via p70S6K2-dependent activation of the Hedgehog/GLI1 and Wnt/β-catenin pathways. In summary, the interplay between circRNAs and RBPs could be a common mechanism that is deeply involved in diverse physiological processes.

**Angio-CircRs act as miRNA sponges**

It is well established that circRNAs sponge diverse miRNAs, which is the most extensive mechanism to regulate tumor angiogenesis. Earlier studies identified many miRNA-binding sites on circRNAs. In tumor cells, circRNAs can also sponge miRNAs and elevate the expression of angiogenic mediators such as VEGF and VEGFA. A typical example is circ-ATXN1 that can facilitate cell viability, migration, and angiogenesis of glioma-exposed endothelial cells (GECs) by sponging miR-526b-3p to upregulate the expression of angiogenic mediators such as VEGF and VEGFA. As another example, circRNA-MYLK can sponge miR-29a in BCa, further triggering VEGFA/VEGFR2 and Ras/ERK pathways, thereby promoting EMT, angiogenesis, and metastasis. In addition, circRNA-MYLK can sponge miR-513a-5p and upregulate the expression of

![Figure 3. Mechanisms of action of Angio-CircRs in cancer progression](image-url)
VEGFC, thereby promoting cell proliferation, metastasis, and angiogenesis in renal cell carcinoma.\textsuperscript{127} Similarly, in BCa tissues, circ0001429 can increase the expression of VEGFA to promote cell proliferation, migration, and invasion by sponging miR-205-5p.\textsuperscript{126} In CRC, the expression of circ-001971, circCCT3, and circ0056618 was significantly increased, contributing to VEGFA expression. They function as ceRNAs through the adsorption of diverse miRNAs and promote cell proliferation, migration, invasion, and angiogenesis.\textsuperscript{121,122,128}

In addition to VEGF, circRNAs regulate the expression of other angiogenic regulators by modulating miRNAs to control tumor angiogenesis. A study uncovered that circ0020710 acts as a molecular sponge to adsorb miR-370-3p, promoting CXCL12 expression in melanoma. Its downstream CXCL12/CXCR4/CXCR7 axis mediates angiogenesis, tumor development, and recruitment of immunosuppressive cells.\textsuperscript{129} circPRRC2A sponges miR-6776-5p and miR-514a-5p to prevent the degradation of the TRPM3 miRNA, thereby promoting angiogenesis and metastasis of renal cell carcinoma.\textsuperscript{130} Another circRNA, SHKB1, upregulates FOXP1 and FOXP2 expression by sponging miR-544a and miR-379, respectively, in glioma, while FOXP1/FOX2 transcriptionally promote AGGF1 expression to facilitate viability, migration, and tube formation of GECs through the PI3K/AKT/ERK pathway.\textsuperscript{131} Similarly, circ-Dicer1 and circ002136 promote the tube formation of GECs by the sponging of miRNAs and the resulting upregulation of ZIC4 and SOX13.\textsuperscript{132,133} Additionally, in pancreatic ductal adenocarcinoma (PDAC), lsa_circ_001653 promotes the restoration of cell cycle progression, angiogenesis, and invasiveness, sequestering miR-377 and elevating HOXC6 expression.\textsuperscript{134} circ-ASH2L regulates Notch 1 expression by sequestering miR-34a, promoting tumor invasion, proliferation, and angiogenesis.\textsuperscript{135} lsa_circ_0000092 sponges miR-338-3p to upregulate HN1 in HCC, and lsa_circRNA_002178 sponges miR-338-3p to upregulate COL1A1 in breast cancer, thus promoting angiogenesis.\textsuperscript{136,137} On the contrary, circHIPK3 is decreased in BCa and inversely correlates with cancer grade and lymph node metastasis. Functional assays uncovered that circHIPK3 inhibited the expression of heparanase (HPSE) by sponging miR-558.\textsuperscript{133} Altogether, these studies indicate that circRNAs extensively modulate miRNAs to regulate angiogenesis, which provides a novel insight to guide tumor therapy through targeting circRNAs.

**EMERGING PARADIGMS OF IncRNAs AND circRNAs IN ANGIogenesis**

**Angio-LncRs and Angio-CircRs induce cancer onset and progression**

Increasing numbers of studies have shown that IncRNAs and circRNAs orchestrate tumor proliferation, migration, invasion, metastasis, and the local microenvironment for tumor cell colonization.\textsuperscript{138,139} Herein, we provide examples of studies on Angio-LncRs and Angio-CircRs from the perspective of immune escape, EMT and migration, invasation and extravasation, and the pre-metastasis niche (Figure 4). Immune escape has always been considered a crucial step in tumor development and progression, including the recruitment of immune cells and macrophage M1/M2 (classically activated/alternatively activated) polarization.\textsuperscript{140,141} IncRNAs can serve as key regulators of macrophages to impact innate immunity. For example, IncRNA-MM2P and SNHG15 promoted M2 polarization of macrophages, and CamK-A was involved in macrophage recruitment.\textsuperscript{142,143,144} EMT is a cellular process that causes cancer cells to attenuate epithelial characteristics and acquire mesenchymal characteristics, separating them from neighboring cells and allowing them to migrate and invade more efficiently.\textsuperscript{143–145} GATA6-AS increases TGF-β-induced EMT and promotes the formation of blood vessels in mice.\textsuperscript{94} MALAT1 promotes angiogenesis and EMT in CRC by elevating VEGFA, SLUG, and TWIST expression.\textsuperscript{71} The circRNA-MYLK contributes to EMT and BCa development by activating VEGFA/VEGFR2 and its downstream Ras/ERK signaling pathways.\textsuperscript{119} Another circRNA, circ-CSPF1, promotes EMT and OC development by upregulating EMT-related markers.\textsuperscript{146} Intravasation and extravasation are the biological processes by which invasive cancer cells pass in and out of circulation through the walls of blood vessels and spread to the site of metastasis.\textsuperscript{147} A recent study uncovered that circ-CCAC1 could destroy the endothelial barrier integrity and promote angiogenesis by interacting with EZH2.\textsuperscript{12} IncRNA-ATB can mediate TGF-β to promote EMT, invasion, intravasation, and colonization of tumor cells.\textsuperscript{148,149} Furthermore, the pre-metastatic niche is the changed supportive microenvironment of distant organs and tissues before the tumor cells reach the site of metastasis, including the changes in cellular constituents, immune status, blood supply, and extracellular matrix (ECM). In particular, fibroblasts and ECM dynamics are involved in the adhesion, growth, and metastasis of tumor cells.\textsuperscript{150,151} H19 promotes the expression of key ECM-remodeling genes through a variety of mechanisms.\textsuperscript{152} Additionally, functional enrichment analysis suggested that CDR1as was associated with angiogenesis, ECM organization, and especially interaction with ECM receptor to modulate the tumor microenvironment.\textsuperscript{153} MALAT1 and the IncRNA XIST can mediate the expression and secretion of fibroblast growth factor (FGF).\textsuperscript{154,155} Current studies indicate that IncRNAs and circRNAs manipulate the progression of diverse cancers via modulating the tumor microenvironment. The new links between Angio-LncRs/Angio-CircRs and multistep tumor progression will open up a new perspective for ncRNA-induced angiogenesis, thus accelerating rational development of antitumor treatment strategies from an anti-angiogenic perspective.

**The potential clinical application of IncRNAs and circRNAs**

As discussed above, Angio-LncRs and Angio-CircRs contribute to tumor progression by manipulating a plethora of phenotypes, including tumor angiogenesis, cell proliferation, EMT, apoptosis, and metastasis. Therefore, Angio-LncRs and Angio-CircRs could act as promising biomarkers and efficacious therapeutic targets for tumor therapy. To date, only a small portion of IncRNAs and circRNAs have been used as promising tools for diagnostic, prognostic, and therapeutic biomarkers in the clinical application for...
A few tumor Angio-LncRs, such as H19, MALAT1 and HULC, can be used as plasma biomarkers in a plethora of cancers. In the case of tumor Angio-CircRs, circHIPK3 can be used as a biomarker for the prognosis of various tumors and new therapies in patients with NPC. hsa-circRNA-002178 could be used as a potential non-invasive biomarker for the early detection of LUAD and could act as a potential target of immune therapy. However, diverse functional identifications need to be explored in vivo and in vitro to target Angio-LncRs/Angio-CircRs as novel and promising therapeutic options in the clinical setting.

Targeting Angio-LncRs and Angio-CircRs might represent a promising strategy for inhibiting tumor development and progression. Currently, RNA-based therapeutic approaches mainly include RNA interference (RNAi) and antisense oligonucleotides (ASOs), designed to target diverse RNAs and specific regions. The first RNAi-based drug patisiran was approved by the US Food and Drug Administration to treat hereditary transthyretin amyloidosis. ASOs have also displayed a promising prospect in targeting lncRNAs in a study on patients with Angelman syndrome. Similarly, intravenous treatment with ASOs targeting lncRNAs TUG1 and PVT1 can inhibit tumor proliferation and differentiation by combining with the drug.
In vivo RNAi and pharmacological therapeutic strategy targeting FLANC significantly suppressed tumor angiogenesis and CRC metastasis, while specific small interfering RNAs (siRNAs) significantly suppress the metastases. Using a double-stranded DNA plasmid, DTA-H19-targeting cancer cells that overexpress H19 induced diphtheria toxin-A expression, thereby reducing the size of multiple tumor types. In addition, emerging research suggests that the peptides encoded by Angio-CircRs have increasing potential for tumor therapy. As in TNBC, the peptide ASRPS encoded by LINC00908 can inhibit tumor angiogenesis, and the peptide CIP2A-BP encoded by LINC00665 can significantly reduce invasion and metastasis, indicating that they are effective anti-TNBC peptides. In the future, the combinatorial application of conventional therapy with targeting Angio-LncRs or Angio-CircRs adds synergy in anti-angiogenic cancer therapy, which broadens our understanding of the progress made in cancer therapy.

Accumulating studies have uncovered that a variety of Angio-LncRs and Angio-CircRs regulate chemotherapy resistance, radiotherapy sensitivity, and immunotherapeutic tolerance. For example, some Angio-LncRs, such as MALAT1, MEG3, and CRNDE, are involved in resistance to 5-fluorouracil, adriamycin, mitomycin, and oxaliplatin in distinct cancers. Similarly, Angio-CircRs also influence chemotherapy resistance in different cancers. For example, the upregulation of circ-SMARCA5 can enhance the sensitivity of intrahepatic CCA cells to cisplatin and gemcitabine. hsa_circ_0023404 was upregulated in cervical tumor cells to promote cisplatin resistance. In addition, cZNF292 increased the hypoxic tumor cell radiosensitivity of radiotherapy in HCC. hsa_circRNA-002178 can enhance the expression of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) in tumor cells and T cells and enhance immunotherapy tolerance. To date, several anti-angiogenic drugs such as bevacizumab have been approved in targeting angiogenesis for tumor therapy. However, there are no clinical applications for targeting Angio-LncRs/Angio-CircRs in tumor therapy. Therefore, the detection of lncRNA and circRNA levels in various patients could predict the efficacy and safety of various drugs and suggest implementing different therapeutic doses or methods to promote individualized treatment regimens. Altogether, the development of new biomarkers and treatment strategies for Angio-LncRs and Angio-CircRs could develop potential clinical significance for tumor treatment.

CONCLUSIONS AND FUTURE PERSPECTIVES
This review emphasizes the emerging functions and mechanisms of angiogenic lncRNAs and circRNAs in tumor progression and their potential diagnostic and therapeutic applications. Importantly, Angio-LncRs and Angio-CircRs orchestrate the carcinogenesis and development of diverse cancers via a broad repertoire of molecular mechanisms. We highlight the common dysregulation of...
Angio-LncRs and Angio-CircRs in tumor progression to manipulate multiple signaling pathways associated with angiogenesis, cell proliferation, EMT, apoptosis, and metastasis. Additionally, exploring the functional commonalities between IncRNAs and circRNAs may provide a vital hint to understand the biological functions of ncRNAs and suggest clinical values of Angio-LncRs and Angio-CircRs in tumor angiogenesis.

Since the exact mechanisms of action of IncRNAs and circRNAs have not been fully elucidated, their known roles in cancer biology may represent only the tip of the iceberg. Some Angio-LncRs and Angio-CircRs may have multiple levels of functional mechanisms in tumor angiogenesis. For instance, PVT1 can not only regulate chromatin remodeling, transcriptional activation, and protein modification, but it also can adsorb a variety of miRNAs regulating downstream target genes. Besides affecting angiogenesis, Angio-LncRs and Angio-CircRs also influence multiple different functional phenotypes. For example, MALAT1 regulates EMT, migration, invasion, metastasis, and ECM remodeling. In that this review focuses on the roles of Angio-LncRs and Angio-CircRs in tumor angiogenesis, we did not elaborate on other functional mechanisms.

Although IncRNAs and circRNAs have shown attractive breakthroughs and prospects, the field is yet to conquer certain challenges and limitations. Utilizing or developing novel technologies, such as CRISPR-mediated gene editing and genome-wide chromatin interrogation, will continue to accelerate advances in preclinical studies for antitumor treatment. The development of RNA sequencing (RNA-seq), global run-on sequencing (GRO-seq), and quantitative RT-PCR (qRT-PCR) techniques has greatly improved the ability to determine the transcription and expression of genes and to elucidate the function of ncRNAs. Moreover, siRNA or short hairpin RNA (shRNA) is often used to silence ncRNAs, and the RNA pull-down approach has helped elucidate the interaction between ncRNAs and proteins. Emerging advancements in new technologies and approaches provide exciting opportunities for ncRNA research and its translation to the clinic. However, in vivo treatment strategies related to IncRNAs and circRNAs are still limited because of their poor intracellular uptake and stability. Currently, liposomases, lentiviruses, adenoviruses, exosomes, and nanoparticles are commonly used in vivo delivery systems for IncRNAs and circRNAs. Future studies, combined with novel technologies, should focus on delivering IncRNAs and circRNAs to target cells in a tissue-specific manner.

Despite current challenges and limitations, significant advances in the field of Angio-LncR and Angio-CircR research are nonetheless being made. Recent advances describing the functions and mechanisms of angiogenic IncRNAs and circRNAs facilitate cancer diagnosis. However, there are a series of key questions to be answered. Are a series of angiogenic ncRNAs more promising as diagnostic markers in angiogenic diseases? Does targeting angiogenic ncRNAs have any impact on the expression of essential genes in normal and tumor tissues? Could the combination of targeting ncRNAs and using conventional anti-angiogenic agents enhance therapeutic efficacy in heterogeneous tumors? In essence, exploring the functional commonalities between IncRNAs and circRNAs may provide a vital hint to understand the biological functions of ncRNAs. Understanding the mechanism of interaction between IncRNAs or circRNAs and other biomolecules may identify certain IncRNAs and circRNAs that have the potential to be used as biomarkers or therapeutic targets in tumor angiogenesis; this would be a major advance in the beneficial treatment of cancer patients.

ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation of China (81872412 to H.-W.X.), the Natural Science Foundation of Hubei Province, China (2019CFB591 to Z.M.), the Bureau of Science and Technology of Jinhzhou Municipality, China (2020CB21-35 to Z.M.), and Guangdong Provincial-level Special Funds for Promoting High-quality Economic Development, China (2020032 to Q.Z.).

AUTHOR CONTRIBUTIONS
Z.M. conceived the review. Z.M., H.-W.X., and Q.Z. wrote and revised the manuscript. C.-G.L., J.L., and Y.X. drafted the manuscript and prepared the figures. W.L. and S.-X.F. helped to modify the manuscript. All authors read and approved the final manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Quinn, J.J., and Chang, H.Y. (2016). Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 17, 47–62.
2. Beermann, J., Piccoli, M.T., Viereck, J., and Thum, T. (2016). Non-coding RNAs in development and disease: Background, mechanisms, and therapeutic approaches. Physiol. Rev. 96, 1297–1325.
3. Bao, Z., Yang, Z., Huang, Z., Zhou, Y., Cui, Q., and Dong, D. (2019). LncRNA Disease 2.0: an updated database of long non-coding RNA-associated diseases. Nucleic Acids Res. 47 (D1), D1034–D1037.
4. Ponting, C.P., Oliver, P.L., and Reik, W. (2009). Evolution and functions of long noncoding RNAs. Cell 136, 629–641.
5. Kopp, F., and Mendell, J.T. (2018). Functional classification and experimental dissection of long noncoding RNAs. Cell 172, 393–407.
6. Kristensen, L.S., Andersen, M.S., Stagsted, L.V.W., Ebbesen, K.K., Hansen, T.R., and Kjems, J. (2019). The biogenesis, biology and characterization of circular RNAs. Nat. Rev. Genet. 20, 675–691.
7. Li, X., Yang, L., and Chen, L.L. (2018). The biogenesis, functions, and challenges of circular RNAs. Mol. Cell 72, 428–442.
8. Batista, P.J., and Chang, H.Y. (2013). Long noncoding RNAs: Cellular address codes in development and disease. Cell 152, 1298–1307.
9. Flynn, R.A., and Chang, H.Y. (2014). Long noncoding RNAs in cell fate programming and reprogramming. Cell Stem Cell 14, 752–761.
10. Cheng, J., Meng, J., Zhu, L., and Peng, Y. (2020). Exosomal noncoding RNAs in glioma: Biological functions and potential clinical applications. Mol. Cancer 19, 66.
11. Niu, Y., Yao, J., Chen, Y., Wang, C., Luo, M., Zhang, B., Zhou, M., Wang, J.E., Fang, Y.Y., Kumar, A., et al. (2020). HIF2-induced long noncoding RNA RAB11B-AS1 promotes hypoxia-mediated angiogenesis and breast cancer metastasis. Cancer Res. 80, 964–975.
12. Xu, Y., Leng, K., Yao, Y., Kang, P., Liao, G., Han, Y., Shi, G., Ji, D., Huang, P., Zheng, W., et al. (2021). A circular RNA, cho1angiofibrocarcinoma-associated circular RNA 1,
Review

35. Menczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiek, S.D., Gregersen, L.H., Munschauer, M., et al. (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333–338.

36. Hansen, T.B., Jensen, T.I., Clausen, B.H., Bramsen, J.B., Finsen, B., Damgaard, C.K., and Kjems, J. (2013). Natural RNA circle functions as efficient microRNA sponges. Nature 495, 384–388.

37. Faghihi, M.A., Modarresi, F., Khalâl, A.M., Wood, D.E., Sahagan, B.G., Morgan, T.E., Finch, C.E., St Laurent, G., 3rd, Kenny, P.J., and Wahlstedt, C. (2008). Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of β-secretase. Nat. Med. 14, 723–730.

38. Gong, C., and Maquat, L.E. (2011). IncRNAs transactivate Staufen-mediated mRNA decay by duplexing with 3′ UTRs via Alu elements. Nature 470, 284–288.

39. Ashwal-Fluss, R., Meyer, M., Pamudurti, N.R., Ivanov, A., Bartok, O., Hanan, M., Evantal, N., Menczak, S., Rajewsky, N., and Kadener, S. (2014). circRNA biogenesis competes with pre-mRNA splicing. Mol. Cell 56, 55–66.

40. Zhang, S., Zhao, B.S., Zhou, A., Lin, K., Zheng, S., Lu, Z., Chen, Y., Sulman, E.P., Xie, K., Bogler, O., et al. (2017). m6A demethylase ALKBH5 maintains tumorigency of glioblastoma stem-like cells by sustaining FOXP1 expression and cell proliferation program. Cancer Cell 31, 591–606.e6.

41. Yang, Y., Fan, X., Mao, M., Song, X., Wu, Z., Zhang, Y., Jin, Y., Yang, Y., Chen, L.L., Wang, Y., et al. (2017). Extensive translation of circular RNAs driven by 5′-methyldenosine. Cell Res. 27, 626–641.

42. Yoon, J.H., Abdelmohsen, K., Kim, J., Yang, X., Martindale, J.L., Tominga-Yamanaka, K., White, E.J., Orijo, A.V., Rinn, J.L., Kreft, S.G., et al. (2013). Scaffold function of long non-coding RNA HOTAIR in protein ubiquitination. Nat. Commun. 4, 2939.

43. Wang, P., Xue, Y., Han, Y., Lin, L., Wu, C., Xu, S., Jiang, Z., Xu, J., Liu, Q., and Cao, X. (2014). The STAT3-binding long noncoding RNA Inc-DC controls human dendritic cell differentiation. Science 344, 310–313.

44. Anderson, D.M., Anderson, K.M., Chang, C.L., Makarewicz, C.A., Nelson, B.R., McAnally, J.R., Kasaragod, P., Shelton, J.M., Liou, J., Basel-Duby, R., and Olson, E.N. (2015). A microepitode encoded by a putative long noncoding RNA regulates muscle performance. Cell 160, 595–606.

45. Legnini, I., Di Timoteo, G., Rossi, F., Morlando, M., Briganti, F., Shandier, O., Fatica, A., Santini, T., Andronache, A., Wade, M., et al. (2017). circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol. Cell 66, 37–69.

46. Cho, W.C., Jour, G., and Aung, P.P. (2019). Role of angiogenesis in melanoma progression: Update on key angiogenic mechanisms and other associated components. Semin. Cancer Biol. 59, 175–186.

47. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: The next generation. Cell 144, 646–674.

48. Bottaro, D.P., and Liotta, L.A. (2003). Cancer: Out of air is not out of action. Nature 423, 593–595.

49. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordanò, S., and Comoglio, P.M. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347–361.

50. Eben, J.M., and Kerbel, R.S. (2011). Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210–221.

51. Blagosklonny, M.V. (2004). Antiangiogenic therapy and tumor progression. Cancer Cell 1, 1367–1376.

52. Chatterjee, S., Heukamp, L.C., Siebald, M., Schöttl, J., Wieland, C., Pfeifer, M., Frasca, D., Koker, M., König, K., Meder, L., et al. (2013). Tumor VEGF/VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J. Clin. Invest. 123, 1732–1740.

53. Siekmann, A.F., and Lawson, N.D. (2007). Notch signalling and the regulation of angiogenesis. Cell Adhes. Migr. 1, 104–106.

54. Fantin, A., Schwarz, Q., Davidson, K., Normando, E.M., Denti, L., and Ruhrberg, C. (2011). The cytoplasmic domain of neuropilin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins. Development 138, 4185–4191.
55. Li, Y., Wu, Z., Yuan, J., Sun, L., Lin, L., Huang, N., Bin, J., Liao, Y., and Liao, W. (2017). Long non-coding RNA MALAT1 promotes gastric cancer tumorigenesis and metastasis by regulating vasculogenic mimicry and angiogenesis. Cancer Lett. 395, 31–44.

56. Yuan, Z., Bian, Y., Ma, X., Tang, Z., Chen, N., and Shen, M. (2019). IncRNA H19 knockdown in human amniotic mesenchymal stem cells suppresses angiogenesis by associating with EZH2 and activating vasohupin-1. Stem Cells Dev. 28, 781–790.

57. Wang, L.L., Zong, Z.H., Liu, Y., Guan, X., Chen, S., and Zhao, Y. (2019). circRNA promotes tumorigenesis and progression in ovarian cancer by functioning as a miR-302e sponge to positively regulate VEGFA. J. Cell. Mol. Med. 23, 8472–8481.

58. Yu, Z., Zhang, M., Liu, J., Xu, B., Yang, J., Wang, N., Yan, S., Wang, F., He, X., Ji, G., et al. (2018). Long non-coding RNA PVT1 promotes cell proliferation and migration by silencing ANGPT1 expression in cholangiocarcinoma. Mol. Ther. Nucleic Acids 13, 503–513.

59. Peng, Z., Wang, J., Shan, B., Li, B., Peng, W., Dong, Y., Shi, W., Zhao, W., He, X., Ji, G., et al. (2018). Long non-coding RNA AK001058 regulates tumor growth and angiogenesis in colorectal cancer via the miR-150-5p/VEGFA axis. Cell Death Dis. 9, e2278.

60. Fu, W.M., Lu, Y.F., Hu, B.G., Liang, W.C., Zhu, X., Yang, H.D., Li, G., and Zhang, J.F. (2016). Long noncoding RNA Hotair mediated angiogenesis in nasopharyngeal carcinoma. Oncotarget 7, 12047–12059.

61. Yuan, Z., Bian, Y., Ma, X., Tang, Z., Chen, N., and Shen, M. (2019). lncRNA H19 competitively binding to BRG1. J. Cell. Physiol. 234, 22027–22027.

62. Zheng, S., Lin, F., Zhang, M., Mu, N., Ge, X., and Fu, J. (2019). Long non-coding RNA AK001058 regulates tumor growth and angiogenesis in colorectal cancer via methylation of ADAMTS12. Am. J. Transl. Res. 11, 6117–6123.

63. Peng, Z., Wang, J., Shen, B., Li, B., Peng, W., Dong, Y., Shi, W., Zhao, H., He, D., Duan, M., et al. (2018). The long noncoding RNA LINC00313 induces lung adenocarcinoma migration and vasculogenic mimicry through directly binding VBX1. Mol. Cancer 17, 67.

64. Song, Z., Xiao, Z., Liu, X., Cui, M., Li, W., Yang, Z., Li, J., Ye, L., and Zhang, X. (2016). Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphenosine kinase 1 (SPHK1). Oncotarget 7, 241–254.

65. Wang, S., Cao, C.H., Han, K., Zhao, Y.X., Cai, M.Y., Xiong, Z.C., Zhang, J.X., Chen, J.W., Zhong, L.P., Huang, Y., et al. (2019). APC-activated long noncoding RNA inhibits colorectal cancer pathogenesis through reduction of eosinore production. J. Clin. Invest. 129, 727–743.

66. Wang, Y., Wu, Y., Xiao, K., Zhao, Y., Lv, G., Xu, S., and Wu, F. (2020). RPS24c isoforms mediate tumor angiogenesis via promoting the stability of MVH1 in colorectal cancer. Curr. Mol. Med. 20, 388–395.

67. Zhang, Z., Sun, J., Qi, Y., Wang, Y., Dong, W., Wang, J., Ma, F., Zhang, J., and Guo, B. (2020). Long non-coding RNA TPT1-AS1 promotes angiogenesis and metastasis of colorectal cancer through TPT1-AS1/miR-39-5p/VEGFA signaling pathway. Aging (Albany NY) 12, 6191–6205.

68. Yang, C., Zheng, J., Liu, X., Xue, Y., He, Q., Dong, Y., Wang, D., Li, Z., Liu, L., Ma, J., et al. (2020). Role of ANKH/UDLINC00346/ZNF655 feedback loop in regulating the glioma angiogenesis via Staufen1-mediated mRNA decay. Mol. Ther. Nucleic Acids 20, 866–878.

69. Wang, X., Li, L., Zhao, K., Lin, Q., Li, H., Xue, G., We, H., He, L., Liu, D., Xie, H., et al. (2020). A novel IncRNA H11TF7 forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth. Cell Death Differ. 27, 1431–1446.

70. Sang, L.J., Hu, Q.H., Li, G.P., Tian, T., Ma, G.L., Li, Y.X., Liu, Z.X., Pan, R.L., Li, R.H., Piao, H.L., et al. (2018). IncRNA ComK-A regulates Ca2+ signaling-mediated tumor microenvironment remodeling. Mol. Cell 72, 71–83.e7.

71. Pichler, M., Rodriguez-Aguayo, C., Nam, S.Y., Dragomir, M.P., Bayraktar, R., Anfossi, S., Knutsen, E., Ivan, C., Fuentes-Mattei, E., Lee, S.K., et al. (2020). Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. Gut 69, 1818–1831.

72. Cao, J., Dong, R., Jiang, L., Gong, Y., Yuan, M., You, J., Meng, W., Chen, Z., Zhang, N., Weng, Q., et al. (2019). IncRNA-MM2 identified as a modulator of macrophage M2 polarization. Cancer Immunol. Res. 7, 292–305.

73. Hou, Z.H., Xu, X.W., Fu, X.Y., Zhou, L.D., Liu, S.P., and Tan, D.M. (2020). Long non-coding RNA MALAT1 promotes angiogenesis and immunosuppressive properties of HCC cells by sponging miR-140. Am. J. Physiol. Cell Physiol. 318, C649–C663.
92. Comet, I., Rising, E.M., Leblanc, B., and Helin, K. (2016). Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat. Rev. Cancer 16, 803–810.

93. Kim, K.H., and Roberts, C.W. (2016). Targeting EZH2 in cancer. Nat. Med. 22, 128–134.

94. Neumann, P., Jaé, N., Knuß, A., Glaser, S.F., Fouani, Y., Rossbach, O., Krüger, M., John, D., Bindereif, A., Grote, P., et al. (2018). The IncRNA GATA6-AS epigenetically regulates endothelial gene expression via interaction with LOXL2. Nat. Commun. 9, 237.

95. Jung, G., Hernández-Illán, E., Moreira, L., Balaguera, F., and Goel, A. (2020). Epigenetics of colorectal cancer: Biomarker and therapeutic potential. Nat. Rev. Gastroenterol. Hepatol. 17, 111–130.

96. Tay, Y., Rinn, J., and Pandolfi, P.P. (2014). The multilayered complexity of ceRNA crosstalk and competition. Nature 505, 344–352.

97. Mao, Z., Xu, B., He, L., and Zhang, G. (2019). PVT1 promotes angiogenesis by regulating miR-29c/vascular endothelial growth factor (VEGF) signaling pathway in non-small-cell lung cancer (NSCLC). Med. Sci. Monit. 25, 5418–5425.

98. Lin, X., Yang, F., Qi, X., Li, Q., Wang, D., Yi, T., Yin, R., Zhao, X., Zhong, X., and Lin, C. (2019). IncRNA DANCr promotes tumor growth and angiogenesis in ovarian cancer through direct targeting of miR-145. Mol. Carcinog. 58, 2286–2296.

99. Ye, J., Zhu, J., Chen, H., Qian, J., Zhang, L., Wan, Z., Chen, F., Sun, S., Li, W., and Luo, C. (2020). A novel IncRNA-LINC01116 regulates tumorigenesis of glioma by targeting VEGFA. Int. J. Cancer 146, 248–261.

100. Zhao, X., Liu, Y., Li, Z., Zheng, S., Wang, Z., Li, W., Bi, Z., Li, J., Yang, L., Luo, Y., et al. (2018). lnc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. J. Cell. Mol. Med. 22, 655–667.

101. Ma, Y., Yue, X., Liu, X., Xu, C., Cai, H., Wang, P., Li, Z., Li, Z., and Liu, Y. (2017). SNHG15 affects the growth of glioma microvascular endothelial cells by negatively regulating miR-153. Oncol. Rep. 38, 3265–3277.

102. Zhang, J.X., Chen, Z.H., Chen, D.L., Tian, X.P., Wang, C.Y., Zhou, Z.W., Gao, Y., Xu, H., Chi, H., Yang, R., Zheng, X., Zhang, L., Jiang, R., and Chen, J. (2018). lncRNA RP11-352 Molecular Therapy: Oncolytics Vol. 22 September 2021

103. Guo, J., Cai, H., Liu, X., Zheng, J., Liu, Y., Gong, W., Chen, J., Xi, Z., and Xue, Y. (2019). SNHG16 impacts the growth of glioma microvascular endothelial cells by negatively regulating miR-153. Oncol. Rep. 38, 3265–3277.
Review

129. Wei, C.Y., Zhu, M.X., Lu, N.H., Liu, J.Q., Yang, Y.W., Zhang, Y., Shi, Y.D., Feng, Z.H., Li, J.X., Qi, F.Z., and Gu, J.Y. (2020). Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma. Mol. Cancer 19, 84.

130. Li, W., Yang, F.Q., Sun, C.M., Huang, J.H., Zhang, H.M., Li, X., Wang, G.C., Zhang, N., Che, J.P., Zhang, W.T., et al. (2020). circPRRC2A promotes angiogenesis and metastasis through epithelial-mesenchymal transition and upregulates TRPM3 in renal cell carcinoma. Theranostics 10, 4395–4409.

131. He, Q., Zhao, L., Li, Y., Liu, X., Zheng, J., Yu, H., Cai, H., Ma, J., Liu, L., Wang, P., et al. (2018). circ-SHKBP1 regulates the angiogenesis of U87 glioma-exposed endothelial cells through miR-544a/FOX1 and miR-379/FOX2 pathways. Mol. Ther. Nucleic Acids 10, 331–348.

132. He, Q., Zhao, L., Liu, X., Zheng, J., Liu, Y., Liu, L., Ma, J., Cai, H., Li, Z., and Yue, X. (2019). MOV10 binding circ-DICER1 regulates the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4 expression change. J. Exp. Clin. Cancer Res. 38, 9.

133. He, Z., Ruan, X., Liu, X., Zheng, J., Liu, Y., Liu, L., Ma, J., Shao, L., Wang, D., Shen, S., et al. (2019). FUS/circ_002136/miR-138-5p/SOX13 feedback loop regulates angiogenesis in glioma. J. Exp. Clin. Cancer Res. 38, 65.

134. Shi, H., Li, H., Zhen, T., Dong, Y., Pei, X., and Zhang, X. (2020). hsa_circ_001653 implicates in the development of pancreatic ductal adenocarcinoma by regulating microRNA-377-mediated HOXC6 axis. Mol. Ther. Nucleic Acids 20, 252–264.

135. Chen, Y., Li, Z., Zhang, M., Wang, B., Ye, J., Zang, Y., Tang, D., Ma, D., Jin, W., Li, X., and Wang, S. (2019). circ-AHSL2 promotes tumor progression by sponging miR-34A to regulate Notch1 in pancreatic ductal adenocarcinoma. J. Exp. Clin. Cancer Res. 38, 466.

136. Pu, J., Wang, J., Li, W., Lu, Y., Wu, X., Long, X., Luo, C., and Wei, H. (2020). hsa_circ_0000092 promotes hepatocellular carcinoma progression through up-regulating HN1 expression by binding to microRNA-338-3p. J. Cell. Med. Res. published online February 20, 2020. https://doi.org/10.1111/jcrm.15010.

137. Liu, T., Ye, P., Ye, Y., Lu, S., and Han, B. (2020). Circular RNA hsa_circ_002178 silencing retards breast cancer progression via microRNA-328-3p-mediated inhibiting HN1 expression by binding to microRNA-424-5p. Onco Targets Ther. 12, 7095–7109.

138. Chandra Gupta, S., and Nandan Tripathi, Y. (2017). Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int. J. Cancer 140, 1955–1967.

139. Guo, Y., Yang, J., Huang, Q., Hsueh, C., Zheng, J., Wu, C., Chen, H., and Zhou, L. (2019). Circular RNAs and their roles in head and neck cancers. Mol. Cancer 18, 44.

140. Zhou, X., Yin, C., Dang, Y., Ye, F., and Zhang, G. (2015). Identification of the long non-coding RNA H19 as a novel biomarker for diagnosis of gastric cancer. Sci. Rep. 5, 11516.

141. Zidan, H.E., Karam, R.A., El-Seif, O.S., and Abd Elrahman, T.M. (2018). Circulating long non-coding RNA MALAT1 expression as molecular biomarker in Egyptian patients with breast cancer. Cancer Genet. 220, 32–37.

142. Liu, M., Yang, P., Mao, G., Deng, J., Peng, G., Ning, X., Yang, H., and Sun, H. (2019). Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis. Int. J. Surg. 72, 206–213.

143. Li, J., Wang, X., Tang, J., Jiang, R., Zhang, W., Ji, J., and Sun, B. (2015). HULC and MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma. Cell. Physiol. Biochem. 37, 687–696.

144. Wang, J., Zhao, X., Wang, Y., Ren, F., Sun, D., Yan, Y., Kong, X., Bu, J., Liu, M., and Xu, S. (2020). circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in glioma: A systematic review and meta-analysis. Int. J. Cancer 146, 3885–3896.

145. Adams, D., Gonzalez-Duarte, A., O’Riordan, W.D., Yang, C.C., Ueda, M., Kristen, A.V., Tourneur, I., Schmidt, H.H., Goebbels, T., Berk, J.L., et al. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11–21.

146. Meng, L., Ward, A.J., Chun, S., Bennett, C.F., Beaudet, A.L., and Rigo, F. (2015). Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 518, 409–412.

147. Katsushima, K., Natsume, A., Ohka, F., Shinjo, K., Hatanaka, A., Ichimura, N., Sato, S., Takahashi, S., Kinumura, H., Totsuka, Y., et al. (2016). Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat. Commun. 7, 13616.

148. Xu, Y., Li, Y., Jin, J., Han, G., Sun, C., Pozzi, M.P., Hau, L., Scott, A., Wang, Y., Ma, L., et al. (2019). IncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol. Cancer 18, 141.

149. Zhu, A.D., Sun, Y.Y., Ma, Q.J., and Xu, F. (2019). Retraction. J. Cell. Biochem. 120, 14360–14371. Published online June 4, 2021. https://doi.org/10.1002/jcb.30000.

150. Steeg, P.S. (2016). Targeting metastasis. Nat. Rev. Cancer 16, 201–218.

151. Liu, Y., and Cao, X. (2016). Characteristics and significance of the pre-metastatic niche. Cancer Cell 30, 668–681.

152. Cao, T., Jiang, Y., Wang, Z., Zhang, N., Al-Hendy, A., Mamillapalli, R., Kalen, A.N., Kodaman, P., Taylor, H.S., Li, D., and Huang, Y. (2019). H19 IncRNA identified as a master regulator of genes that drive uterine leiomyomas. Oncogene 38, 5356–5366.

153. Zou, Y., Zheng, S., Deng, X., Yang, A., Xie, X., Tang, H., and Xie, X. (2019). The role of circular RNA CDR1as/CRIS-7 in regulating tumor microenvironment: A pan-cancer analysis. Biomolecules 9, 429.

154. Huang, J.K., Ma, L., Song, W.H., Lu, B.Y., Huang, Y.R., Dong, H.M., Ma, X.K., Zhu, Z.Z., and Zhou, R. (2017). IncRNA MALAT1 promotes angiogenesis of thyroid cancer by modulating tumor-associated macrophage FGFR2 protein secretion. J. Cell. Biochem. J18, 4821–4830.

155. Zhou, K., Li, S., Du, G., Fan, Y., Wu, P., Sun, H., and Zhang, T. (2019). IncRNA XIST depletion prevents cancer progression in invasive pituitary neuroendocrine tumor by inhibiting bFGF via upregulation of microRNA-424-5p. Oncotargets Thér. 12, 7095–7109.

156. Guo, B., Wu, S., Zhu, X., Zhang, L., Deng, J., Li, F., Wang, Y., Zhang, S., Wu, R., Lu, J., et al. (2012). Targeting the Notch-regulated non-coding RNA H19 as a novel biomarker for diagnosis of gastric cancer. Sci. Rep. 5, 11516.

157. Mizrahi, A., Czerniak, A., Levy, T., Amiur, S., Gallula, J., Matouk, I., Abu-lail, R., Mizrahi, A., Czerniak, A., Levy, T., Amiur, S., Gallula, J., Matouk, I., Abu-lail, R., et al. (2018). circ-SHKBP1 regulates the angiogenesis of glioma. J. Exp. Clin. Cancer Res. 37, 6.

158. Cao, T., Jiang, Y., Wang, Z., Zhang, N., Al-Hendy, A., Mamillapalli, R., Kalen, A.N., Kodaman, P., Taylor, H.S., Li, D., and Huang, Y. (2019). H19 IncRNA identified as a master regulator of genes that drive uterine leiomyomas. Oncogene 38, 5356–5366.
carcinoma cells via modulating autophagy. Biochem. Biophys. Res. Commun. 478, 1067–1073.

170. Wang, H., Li, H., Zhang, L., and Yang, D. (2018). Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis. Biomed. Pharmacother. 106, 1607–1615.

171. Han, P., Li, J.W., Zhang, B.M., Lv, J.C., Li, Y.M., Gu, X.Y., Yu, Z.W., Jia, Y.H., Bai, X.F., Li, L., et al. (2017). The IncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. Mol. Cancer 16, 9.

172. Lu, Q., and Fang, T. (2020). Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma. J. Clin. Lab. Anal. 34, e25138.

173. Guo, J., Chen, M., Ai, G., Mao, W., Li, H., and Zhou, J. (2019). hsa_circ_002404 enhances cervical cancer metastasis and chemoresistance through VEGFA and autophagy signaling by sponging miR-5047. Biomed. Pharmacother. 115, 108957.

174. Yang, W., Liu, Y., Gao, R., Xu, Z., and Sun, T. (2019). Knockdown of cZNF292 suppressed hypoxic human hepatoma SMMC7721 cell proliferation, vasculogenic mimicry, and radioresistance. Cell. Signal. 60, 122–135.

175. Ghafoori-Fard, S., Omrani, M.D., and Taheri, M. (2020). Long noncoding RNA PVT1: A highly dysregulated gene in malignancy. J. Cell. Physiol. 235, 818–835.

176. Lei, L., Chen, J., Huang, J., Lu, J., Pei, S., Ding, S., Kang, L., Xiao, R., and Zeng, Q. (2018). Functions and regulatory mechanisms of metastasis-associated lung adenocarcinoma transcript 1. J. Cell. Physiol. 234, 134–151.

177. Huang, A., Zheng, H., Wu, Z., Chen, M., and Huang, Y. (2020). Circular RNA-protein interactions: Functions, mechanisms, and identification. Theranostics 10, 3503–3517.

178. Dong, Y., Siegwalt, D.J., and Anderson, D.G. (2019). Strategies, design, and chemistry in siRNA delivery systems. Adv. Drug Deliv. Rev. 144, 133–147.

179. Wang, D., Zhang, F., and Gao, G. (2020). CRISPR-based therapeutic genome editing: Strategies and in vivo delivery by AAV vectors. Cell 181, 136–150.

180. Xu, C.F., Chen, G.J., Luo, Y.L., Zhang, Y., Zhao, G., Lu, Z.D., Czarna, A., Gu, Z., and Wang, J. (2021). Rational designs of in vivo CRISPR-Cas delivery systems. Adv. Drug Deliv. Rev. 168, 3–29.

181. Tay, A., and Melosh, N. (2019). Nanostructured materials for intracellular cargo delivery. Acc. Chem. Res. 52, 2462–2471.